Fresenius acquires remaining 45% of mAbxience
- Location
- Madrid · 🇪🇸 Spain / Germany
- Sector
- Pharma
- Organisations
- Fresenius ↔ mAbxience (Verkäufer: Insud Pharma, Invim Corporativo)
- Transaction
- Acquisition of remaining shares (45%)
- Volume
- up to €750m
- Status
- completed
Fresenius has bought the remaining 45% of Madrid-based biosimilars maker mAbxience from Insud Pharma and Invim Corporativo and now owns the company outright; the price is up to €750m, of which €50m depends on site approvals. Signing and completion took place on 30 September 2026 with no regulatory approval required; Fresenius had acquired its 55% majority stake in August 2022, and mAbxience is part of Fresenius Kabi's Biopharma business (Fresenius via EQS, 01.10.2026).
Source: webdisclosure.com ↗ · Archived copy ↗
Further sources: mabxience.com ↗ (Archived copy ↗)
Evidence: 2 independent sources · archived copy saved · How well sourced is Eurotrack?
More from: 🇪🇸 Spain · 🇩🇪 Germany